Expert Review Logo
Welcome Guest user | Log in | Athens Login | Shibboleth Login | Register
Resources
Register
For Authors
For Librarians
For Advertisers
Services
Subscriptions/Pricing
Reprints
Advertising
Press Releases/News
Help
Downloads/Links
2008/9 Catalogue
Library Recommendation
Summary
August 2007, Vol. 7, No. 8, Pages 981-988 , DOI 10.1586/14737175.7.8.981
(doi:10.1586/14737175.7.8.981)

Review
When attention-deficit/hyperactivity disorder co-occurs with anxiety disorders: effects on treatment
Katharina Manassis



Anxiety disorders (ANX) and attention-deficit/hyperactivity disorder (ADHD) commonly co-occur; this comorbidity is associated with a high degree of impairment and a poor long-term prognosis. In this review, the nature of this comorbidity and its treatment will be described, and an approach to treating children with ANX + ADHD will be presented. The etiology of ANX + ADHD is controversial, with biological, developmental, environmental and cognitive factors examined in various studies. There is increasing evidence that ANX + ADHD may be distinct from each separate disorder, and may represent a neuropsychiatric condition that involves dysregulation in both anxiety and ADHD domains. Treatment usually requires a combination of medication and psychotherapeutic intervention. Stimulant medications have been found most helpful so far compared with other medications, although atomoxetine is also being studied. There is limited evidence for selective serotonin reuptake inhibitors, and their potential for behavioral activation may be problematic in these children. Intensive behavior modification was shown to be beneficial in conjunction with medication for ANX + ADHD in a multimodal treatment study of children with ADHD. Cognitive–behavioral therapy has been used to address anxiety symptoms, but may need to be individualized in ANX + ADHD as cognitive limitations and ADHD behaviors may otherwise interfere. Parental anxious or ADHD traits and the child’s developmental level must also be considered to optimize treatment.

Full Text PDF (98 KB) PDF Plus (172 KB)

Users who read this article also read:

The PRoFESS trial: future impact on secondary stroke prevention
Hans-Christoph Diener
Expert Review of Neurotherapeutics, Sep 2007, Vol. 7, No. 9, Pages 1085-1091.
Summary | Full Text | PDF (119 KB) | PDF Plus (159 KB) | Add to Favorites | Related 
Clinical assessment and treatment of attention deficit hyperactivity disorder in adults
Philip Asherson
Expert Review of Neurotherapeutics, Jul 2005, Vol. 5, No. 4, Pages 525-539.
Summary | Full Text | PDF (155 KB) | PDF Plus (222 KB) | Add to Favorites | Related 
Statin myopathy as a metabolic muscle disease
Paul S Phillips, Richard H Haas
Expert Review of Cardiovascular Therapy, Aug 2008, Vol. 6, No. 7, Pages 971-978.
Summary | Full Text | PDF (3360 KB) | PDF Plus (3238 KB) | Add to Favorites | Related 
Neurobiology of bipolar disorder
Andrew R Newberg, Lisa A Catapano, Carlos A Zarate, Husseini K Manji
Expert Review of Neurotherapeutics, Jan 2008, Vol. 8, No. 1, Pages 93-110.
Summary | Full Text | PDF (2013 KB) | PDF Plus (2068 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (98 KB)
View PDF Plus (172 KB)
Add to favorites
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Author:
Katharina Manassis
Keywords:
anxiety disorder
attention-deficit/hyperactivity disorder
child psychiatry
comorbidity
psychopharmacology
psychotherapy


Expert Reviews Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK
Business Office: Tel +44 (0)20 8371 6080 · Fax +44 (0)20 8371 6099 
Editorial Office: Tel +44 (0)20 8371 6090 · Fax +44 (0)20 8343 2313
We welcome your Feedback. See our Privacy Statement and Terms and Conditions.